單純皰疹病毒治療市場（依藥物類型、給藥途徑及地區）

Herpes Simplex Virus Treatment Market, By Drug Type, By Route of Administration, By Geography

出版日期: 2025年05月15日 | 出版商:

Coherent Market Insights | 英文 171 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

單純皰疹病毒治療市場規模預計在 2025 年為 26.536 億美元，預計到 2032 年將達到 39.117 億美元，2025 年至 2032 年的複合年成長率為 5.7%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	26.536億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	5.70%	2032年價值預測	39.117億美元

單純皰疹病毒 (HSV) 是一種會導致生殖器皰疹和口唇皰疹的病毒感染疾病。它是一種感染疾病極強的病毒。 HSV 有兩種類型：HSV-1 和 HSV-2。生殖器皰疹無法治愈，但每日服用抗病毒藥物可以預防或縮短皰疹發作。因此，全球對安全有效的單純皰疹病毒治療的需求日益成長。

市場動態：

單純皰疹病毒感染疾病盛行率的增加、臨床試驗數量的增加、對安全有效的 HSV 治療的需求不斷成長以及人們對單純皰疹病毒認知的提高是預計在預測期內促進全球單純皰疹病毒治療市場成長的關鍵因素。

例如，2021年10月，聯合生物製藥、上海市公共衛生臨床中心和上海中大微生物學系合作，研究了首創長效藥物UB-621治療由單純皰疹病毒1型和2型（HSV 1和2）引起的生殖器皰疹的療效。此外，世界衛生組織（WHO）及其合作夥伴正在支持進行研究，以開發預防和控制單純皰疹病毒感染的新策略。

本研究的主要特點

本報告對全球單純皰疹病毒治療市場進行了詳細分析，並提供了預測期 2025-2032 的市場規模和年複合成長率(CAGR)，以 2024 年為基準年。
它還強調了各個領域的潛在商機，並說明了該市場的引人注目的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
該報告涵蓋了全球單純皰疹病毒治療市場的主要企業概況，基於以下參數，例如公司亮點、產品系列、關鍵亮點、財務績效和策略。
本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球單純皰疹病毒治療市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
相關人員可以透過用於分析全球單純皰疹病毒治療市場的各種策略矩陣來更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 2,653.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.70%	2032 Value Projection:	USD 3,911.7 Mn

The herpes simplex virus (HSV) is a viral infection that causes genital and oral herpes. It is a very contagious virus that causes infections. There are two types of HSV, such as HSV-1 and HSV-2. There is no cure for genital herpes, however, daily use of antiviral medicines can prevent or shorten outbreaks, and reduce the chance of spreading it to others. Thus, there is an increasing demand for safe and effective herpes simplex virus treatment worldwide.

Market Dynamics:

Increase in prevalence of infections of the herpes simplex virus, rise in number of clinical trials, increase in demand for safe and effective HSV treatment, and increase in awareness among people about herpes simplex virus are major factors expected to augment the growth of the global herpes simplex virus treatment market over the forecast period.

For instance, in October 2021, United BioPharma, Shanghai Public Health Clinical Centre, and Department of Microbiology (Cheng Kung University) and Immunology teamed up to investigate the efficacy of UB-621, a best-in-class long-acting medicine for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and 2). Moreover, the World Health Organization (WHO) and partners support research to develop new strategies for prevention and control of HSV infections.

Key features of the study:

This report provides in-depth analysis of the global herpes simplex virus treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global herpes simplex virus treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Fresenius SE & Co. KgaA, Glenmark Pharmaceuticals, Carlsbad Tech, GlaxoSmithKline PLC, Zydus Cadila, Epi Health LLC, Viatris Inc., Apotex Inc., Teva Pharmaceuticals Industries Ltd., and Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.), among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global herpes simplex virus treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herpes simplex virus treatment market.

Detailed Segmentation:

Global Herpes Simplex Virus Treatment Market, By Drug Type:
- Acyclovir
- Valacyclovir
- Famciclovir
- Other Drugs
Global Herpes Simplex Virus Treatment Market, By Route of Administration:
- Oral
- Injection
- Topical
Global Herpes Simplex Virus Treatment Market, By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Fresenius SE & Co. KgaA
- Glenmark Pharmaceuticals
- Carlsbad Tech
- GlaxoSmithKline PLC
- Zydus Cadila
- Epi Health LLC
- Viatris Inc.
- Apotex Inc.
- Teva Pharmaceuticals Industries Ltd.
- Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)

Market Dynamics
- Rise in prevalence of infections of the herpes simplex virus
- Social stigma about sexually transmitted diseases (STDs)
- Increase in demand for safe and effective HSV therapeutics
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Herpes Simplex Virus Treatment Market, By Drug Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Acyclovir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Valacyclovir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Famciclovir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Other Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

5. Global Herpes Simplex Virus Treatment Market, By Route of Administration, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Herpes Simplex Virus Treatment Market, By Geography, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)

7. Competitive Landscape

Fresenius SE & Co. KgaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Carlsbad Tech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Epi Health LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceuticals Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views